Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
C E
CE
Simmons
I
I
Kuchuk
O C
OC
Freedman
T
T
Colgan
A
A
Dodd
K
K
Kulhanek
J
J
Sheiner
G
G
Dranitsaris
M
M
Dowsett
E
E
Folkerd
M J
MJ
Clemons
D000282:Administration, Intravaginal; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D052776:Female Urogenital Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans
D047072:Aromatase Inhibitors; D004958:Estradiol